Will the new target-specific oral anticoagulants improve the treatment of venous thromboembolism?

Editorial on ► Cohen and Dobromirski. Thromb Haemost 2012; 107: 1035-1043.

• References

• 1 Budnitz DS, Lovegrove MC, Shehab N. et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011; 365: 2002-2012.
• 2 Ogilvie IM, Newton N, Welner SA. et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010; 123: 638-645.
• 3 Kearon C, Akl EA, Comerota AJ. et al. Antithrombotic therapy for VTE disease. Antithrombotic Therapy and Prevention of Thrombosis, 9^th Ed: American College of Chest Physicians Evidence-Based Clinical Practice guidelines. Chest 2012; 141 Suppl e419S-e494S.
• 4 Kahn SR. The post-thrombotic syndrome: progress and pitfalls. Brit J Haematol 2006; 134: 357-365.
• 5 Becattini C, Agnelli G, Pesavento R. et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest 2006; 130: 172-175.
• 6 Ansell J, Askin D. New Targets for anticoagulation and future perspectives. Curr Drug Discov Technol. 2011 in press.
• 7 van Ryn J, Stangier J, Haertter S. et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
• 8 Cohen A, Dobromirski M. The use of rivaroxaban for short- and long-term treatment of VTE. J Thromb Haemost 2012; 107: 1035-1043.
• 9 Schulman S, Kearon C, Kakkar AK. for the RECOVER Study Group. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
• 10 Schulman S, Baanstra D, Eriksson H. and the RE-SONATE Study group. et al. Dabigatran vsplacebo for extended maintenance therapy of venous thromboembolism. J Thromb Haemost. 2011 9. (suppl.2): 22 Abstract O-MO-037
• 11 The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 363. 2499-2510.
• 12 Amplify Study. Available at http://www.trialresult-scenter.org/study10328-AMPLIFY-(CV185-056).htm Accessed February 22, 2012.
• 13 Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study). Available at http://www.clinical-trials.gov/ct2/show/NCT00986154?term= NCT00986154&rank=1 Accessed February 22, 2012.
• 14 Hull RD, Raskob GE, Hirsh J. et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. N Engl J Med 1986; 315: 1109-1114.
• 15 Brandjes DP, Heijboer H, Buller Hr. et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis. N Engl J Med 1992; 327: 1485-1489.
• 16 Fiessinger JN, Huisman MV, Davidson BL. et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis. J Am Med Assoc 2005; 293: 681-689.
• 17 Phillips KW, Ansell J. New oral anticoagulants: Will the potential advantages be achieved?. Thromb Haemost 2010; 103: 34-39.
• 18 Ansell J. New oral anticoagulants should not be used as first line agents to prevent thromboembolism in patients with atrial fibrillation. Circulation 2011; 125: 165-170.
• 19 Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49-60.